Tag Archives: research peptides
Tirzepatide and HFpEF: What 3,308 Matched Patients Show
Tirzepatide-treated men and women with HFpEF differed little on cardiovascular outcomes. The authors say the design cannot show effectiveness by sex.
Avexitide: a GLP-1 Blocker Cuts Hypoglycaemia by 55%
Avexitide blocks the GLP-1 receptor instead of activating it. Amylyx reports a 55% cut in hypoglycaemic events in a 78-participant phase 3 trial.
GLP-1 and Mitochondria: A 2026 Review Maps the Axis
GLP-1 drugs touch mitochondrial biogenesis, dynamics and mitophagy. A 2026 Aging Cell review asks how much of that is the receptor, not weight loss.
Semaglutide Cut hsCRP 37.8% in SELECT, Before Weight Loss
Semaglutide lowered hsCRP by 37.8% in SELECT, and the drop appeared by week 4, before major weight loss and also in people who lost no weight.
MOTS-c Neutralised MRSA in Mice: A 2026 eLife Report
MOTS-c is not only a metabolic peptide. An eLife paper reports it kills bacteria directly and reprograms monocytes, making it the first mitochondrial HDP.
Retatrutide and Cholesterol: A Post Hoc Look at 2 Trials
Retatrutide was associated with large drops in atherogenic lipoproteins in two phase 2 trials. The analysis was post hoc, and biomarkers are not events.
Thymosin Beta-4 in Colitis: What a 2026 Mouse Study Found
Thymosin beta-4 turns up in gut inflammation, not just tissue repair. A 2026 mouse study links it to a receptor nobody associated with the peptide before.
GEP44: A 3-in-1 Peptide Designed Around Side Effects
GEP44 is a chimeric peptide built from GLP-1, exendin-4 and PYY3-36. Its design target was tolerability, not more weight loss. All data are preclinical.
Semaglutide in MASH: What a 52-Week Biopsy Trial Found
Semaglutide plus an SGLT2 inhibitor beat monotherapy on every histological number in a 52-week MASH trial, and still missed its primary endpoints.
Tirzepatide and Blood Pressure: 32 Trials, Two Signals
Tirzepatide cut hypertension-related adverse events but raised hypotension-related ones across 32 trials, while semaglutide looked neutral on both counts.